Metabolic Disorders Drugs Market Global Report 2017

Metabolic disorders drugs market covers medications that are used in the treatment of diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, hypoadrenalism and other metabolic diseases. Some of the major drugs used in the treatment metabolic diseases are Lantus (type 1 and 2 diabetes), Januvia (diabetes), and other drugs.

The global metabolic disorders drugs market was estimated to be around $80 billion as of 2016. The metabolic disorders drugs market made up around 7% of the overall pharmaceuticals market in 2016. The metabolic disorders drugs market was the seventh largest market in the global pharmaceutical market in 2016.

Acquisitions
Strategic acquisitions of small companies by market leaders in the market to strengthen their market position is one of the major trend in the market. For instance, in August 2015 Novo Nordisk acquired Calibrium LLC and MB2 LLC, a US based biopharmaceutical research companies. Through the acquisitions Novo Nordisk focuses on expanding its obesity and diabetes product line by integrating Calibrium LLC and MB2 LLC companies.

1. Metabolic Disorders Drugs Market Characteristics;

2. Metabolic Disorders Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Metabolic Disorders Drugs Market Customer Information;

5. Metabolic Disorders Drugs Market Segmentation;
5.1. Global Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 5.2. Global Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Metabolic Disorders Drugs Market Trends And Strategies;

6. Metabolic Disorders Drugs Market Regional And Country Analysis;
6.1. Global Metabolic Disorders Drugs Market, 2016, By Region; 6.2. Global Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Metabolic Disorders Drugs Market, 2016, By Country; 6.4. Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8.Global Pharmaceutical Drugs Market Segments, 2016, By Country;

7. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors;
7.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global;

8. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country;

9. Metabolic Disorders Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Diabetes, 2015, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Metabolic Disorders Drugs Market;
10.1.1. Asia-Pacific Metabolic Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.2. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis; 10.3. China Metabolic Disorders Drugs Market; 10.3.1. China Metabolic Disorders Drugs Market Overview; 10.3.2. China Metabolic Disorders Drugs Historic Market, 2012 - 2016; 10.3.3. China Metabolic D4isorders Forecast Market, 2016 - 2020; 10.3.4. China Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.3.5. China Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 10.4. India Metabolic Disorders Drugs Market; 10.4.1. India Metabolic Disorders Drugs Market Overview; 10.4.2. India Metabolic Disorders Drugs Historic Market, 2012 - 2016; 10.4.3. India Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 10.4.4. India Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.4.5. India Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 10.5. Japan Metabolic Disorders Drugs Market; 10.5.1. Japan Metabolic Disorders Drugs Market Overview; 10.5.2. Japan Metabolic Disorders Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.5.5. Japan Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 10.6. Australia Metabolic Disorders Drugs Market; 10.6.1. Australia Metabolic Disorders Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.6.4. Australia Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020;

11. Western Europe Metabolic Disorders Drugs Market;
11.1.1. Western Europe Metabolic Disorders Drugs Market Overview; 11.1.2. Western Europe Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.2. Western Europe Metabolic Disorders Drugs Market: Country Analysis; 11.3. UK Metabolic Disorders Drugs Market; 11.3.1. UK Metabolic Disorders Drugs Market Overview; 11.3.2. UK Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.3.3. UK Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.3.5. UK Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 11.4. Germany Metabolic Disorders Drugs Market; 11.4.1. Germany Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.4.4 Germany Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 11.5 France Metabolic Disorders Drugs Market; 11.5.1 France Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.5.2 France Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.5.3 France Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.5.4 France Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 11.6. Italy Metabolic Disorders Drugs Market; 11.6.1. Italy Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.6.4. Italy Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020; 11.7. Spain Metabolic Disorders Drugs Market; 11.7.1. Spain Metabolic Disorders Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.7.4. Spain Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020;

12. Eastern Europe Metabolic Disorders Drugs Market;
12.1.1. Eastern Europe Metabolic Disorders Drugs Market Overview; 12.1.2. Eastern Europe Metabolic Disorders Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.2. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis; 12.3. Russia Metabolic Disorders Drugs Market; 12.3.1. Russia Metabolic Disorders Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.3.4. Russia Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020;

13. North America Metabolic Disorders Drugs Market;
13.1.1. North America Metabolic Disorders Drugs Market Overview; 13.1.2. North America Metabolic Disorders Drugs Historic Market, 2012 - 2016; 13.1.3. North America Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.2. North America Metabolic Disorders Drugs Market: Country Analysis; 13.3. USA Metabolic Disorders Drugs Market; 13.3.1. USA Metabolic Disorders Drugs Historic Market, 2012 - 2016; 13.3.2. USA Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.3.4. USA Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020;

14. South America Metabolic Disorders Drugs Market;
14.1.1. South America Metabolic Disorders Drugs Market Overview; 14.1.2. South America Metabolic Disorders Drugs Historic Market, 2012 - 2016; 14.1.3. South America Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.2. South America Metabolic Disorders Drugs Market: Country Analysis; 14.3. Brazil Metabolic Disorders Drugs Market; 14.3.1. Brazil Metabolic Disorders Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.3.4. Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020;

15. Middle East Metabolic Disorders Drugs Market;
15.1.1. Middle East Metabolic Disorders Drugs Market Overview; 15.1.2. Middle East Metabolic Disorders Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

16. Africa Metabolic Disorders Drugs Market;
16.1.1. Africa Metabolic Disorders Drugs Market Overview; 16.1.2. Africa Metabolic Disorders Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Metabolic Disorders Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

17. Metabolic Disorders Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Novo Nordisk; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Sanofi; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Merck & Co.; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Eli Lilly; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Astrazeneca PLC; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.4. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer